Hemoglobin C (HbC) is a clinically significant structural hemoglobin variant arising from a single amino-acid substitution within the β-globin chain. Accurate detection and discrimination of HbC are critical in hemoglobinopathy diagnostics, carrier screening, and variant resolution workflows.

HbC results from a missense mutation in the β-globin gene (HBB), producing a Glu6Lys substitution that alters hemoglobin charge distribution, electrophoretic migration, and molecular recognition properties.

Adult human hemoglobin (HbA) is composed of two α-globin and two β-globin chains (α2β2). Hemoglobin C is caused by:

• A point mutation in codon 6 of the β-globin gene
• Glutamic acid (Glu) → Lysine (Lys) substitution
• Altered electrostatic properties
• Modified variant-specific epitopes

This substitution generates a structurally stable but electrophoretically distinct hemoglobin variant requiring precise discrimination from HbA and other β-chain variants.

Hemoglobin C exhibits distinct physicochemical behavior:

• Reduced net negative charge
• Altered electrophoretic mobility
• Modified chromatographic profiles
• Variant-specific conformational features

These properties underpin the necessity for variant-resolved detection technologies capable of distinguishing HbC from closely related hemoglobin isoforms.

Hemoglobin C is particularly prevalent in West African populations and individuals of African descent. It is associated with:

• Homozygous HbCC states
• Compound heterozygous conditions (HbSC)
• Carrier phenotypes (HbAC)

Accurate HbC identification is essential for differential diagnosis, genetic counseling, and characterization of mixed hemoglobinopathy profiles.

Routine HbC detection relies primarily on separation-based analytical techniques:

• Hemoglobin electrophoresis
• Capillary electrophoresis
• High-performance liquid chromatography (HPLC)
• Isoelectric focusing (IEF)

Despite analytical utility, these methods introduce constraints:

• Instrument-dependent workflows
• Variant co-migration risks
• Laboratory infrastructure requirements
• Limited compatibility with rapid diagnostic formats

These limitations drive interest in antibody-based variant discrimination strategies.

Discrimination of HbC at the molecular level requires:

• Mutation-resolved epitope targeting
• Specific recognition of β6 substitution effects
• Absence of cross-reactivity with HbA / HbS / HbE
• Robust binding across clinical matrices

Monoclonal antibodies provide clonal specificity suitable for variant-level hemoglobin resolution.

SynAbs has developed monoclonal antibodies engineered for HbC-specific detection and assay development applications.

• Targets the HbC mutation-associated epitope
• Enables selective HbC recognition
• Supports variant discrimination strategies
• Suitable for immunoassay integration

These antibodies are designed to resolve HbC from structurally related hemoglobin variants.

HbC-targeting monoclonal antibodies are compatible with antibody-based assay formats:

• Sandwich ELISA
• Competitive immunoassays
• Lateral flow immunoassays (LFIA)
• Point-of-care testing (POCT) platforms
• Variant discrimination assays

Such reagents support diagnostic developers and assay designers working on hemoglobin variant detection technologies.

SynAbs HbC monoclonal antibodies are supplied as development-grade RUO reagents intended for:

• Assay feasibility studies
• Antibody pairing and optimization
• Analytical validation workflows
• Diagnostic prototype development

Final diagnostic performance remains assay-dependent.

Mutation-specific monoclonal antibodies enable:

• Variant-resolved hemoglobin detection
• Immunological discrimination of β-chain variants
• Reduced reliance on separation techniques
• Rapid assay integration possibilities
• High reproducibility and batch consistency

These characteristics position antibody-based HbC detection as a valuable component of modern hemoglobinopathy diagnostic strategies.